PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-02-21
DOI
10.1038/srep43013
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The PTEN protein: cellular localization and post-translational regulation
- (2016) N. R. Leslie et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling
- (2016) Jasmina Paluncic et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
- (2016) Vivek Asati et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia
- (2015) Larry Mansouri et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway
- (2015) A Hunter Shain et al. NATURE GENETICS
- Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer
- (2015) G Sette et al. Cell Death & Disease
- MEK and PI3K inhibition in solid tumors: rationale and evidence to date
- (2015) E. Jokinen et al. Therapeutic Advances in Medical Oncology
- PTEN: Multiple Functions in Human Malignant Tumors
- (2015) Michele Milella et al. Frontiers in Oncology
- p21-activated kinase 1: PAK’ed with potential
- (2015) Christy Ong et al. Oncotarget
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
- (2015) William H. Chappell et al. Oncotarget
- Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades
- (2015) James Andrew McCubrey et al. Oncotarget
- A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
- (2014) A. W. Tolcher et al. ANNALS OF ONCOLOGY
- Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
- (2014) Chunxiao Xu et al. CANCER CELL
- CD44v6 Is a Marker of Constitutive and Reprogrammed Cancer Stem Cells Driving Colon Cancer Metastasis
- (2014) Matilde Todaro et al. Cell Stem Cell
- Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC
- (2014) Ludovica Ciuffreda et al. CURRENT PHARMACEUTICAL DESIGN
- In Vitro Treatment of Melanoma Brain Metastasis by Simultaneously Targeting the MAPK and PI3K Signaling Pathways
- (2014) Inderjit Daphu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
- (2014) Amanda Lassen et al. Molecular Cancer
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts
- (2013) Giovanni Sette et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The complexity of NF-κB signaling in inflammation and cancer
- (2013) Bastian Hoesel et al. Molecular Cancer
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Effects of the combination of RAD001 and docetaxel on breast cancer stem cells
- (2012) Xiaobei Zhang et al. EUROPEAN JOURNAL OF CANCER
- The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
- (2012) Antonella De Luca et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms
- (2012) Ludovica Ciuffreda et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination strategies
- (2012) Maria Rosaria Ricciardi et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Development of Novel Combination Therapies
- (2011) Janet Woodcock et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- PAK1 as a therapeutic target
- (2010) Julia V Kichina et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Thymosin β4 targeting impairs tumorigenic activity of colon cancer stem cells
- (2010) Lucia Ricci-Vitiani et al. FASEB JOURNAL
- Bone Morphogenetic Protein 4 Induces Differentiation of Colorectal Cancer Stem Cells and Increases Their Response to Chemotherapy in Mice
- (2010) Ylenia Lombardo et al. GASTROENTEROLOGY
- Lung cancer stem cells: tools and targets to fight lung cancer
- (2010) A Eramo et al. ONCOGENE
- LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
- (2009) C L Mahoney et al. BRITISH JOURNAL OF CANCER
- Targeting targeted agents: open issues for clinical trial design
- (2009) Emilio Bria et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Cotargeting survival signaling pathways in cancer
- (2008) Steven Grant JOURNAL OF CLINICAL INVESTIGATION
- Deregulation of a STAT3-Interleukin 8 Signaling Pathway Promotes Human Glioblastoma Cell Proliferation and Invasiveness
- (2008) N. de la Iglesia et al. JOURNAL OF NEUROSCIENCE
- Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
- (2008) L S Steelman et al. LEUKEMIA
- The PTEN–PI3K pathway: of feedbacks and cross-talks
- (2008) A Carracedo et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More